Strides Pharma Science Limited has informed the Exchange about Copy of Newspaper Publication - Unaudited financial results for the quarter ended June 30, 2025
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Strides Pharma has published its unaudited consolidated and standalone results for Q1 FY26 in Financial Express and Lokmat, as required under SEBI Listing Regulations. Consolidated revenue from operations stood at ₹11,197.36 Mn, up about 6% YoY from ₹10,543.41 Mn in Q1 FY25. However, consolidated profit after tax from continuing operations fell sharply to ₹1,055.93 Mn from ₹1,614.74 Mn a year ago, a drop of roughly 35% YoY. On a sequential basis, PAT recovered from ₹856.18 Mn in Q4 FY25 to ₹1,055.93 Mn, and basic EPS improved from ₹8.92 to ₹10.81. On a standalone basis, revenue was ₹5,003.74 Mn with a profit after tax of ₹133.47 Mn, slightly higher than ₹108.34 Mn in Q1 FY25. Other equity strengthened to ₹25,978.63 Mn from ₹20,941.93 Mn a year earlier.
Mixed signals for investors: topline growth was healthy, but consolidated bottom line contracted significantly YoY, likely weighing on sentiment. However, the strong sequential rebound from Q4 FY25 in both profit and EPS is a positive sign. The detailed results were already filed with the exchanges earlier, so this newspaper publication is a procedural disclosure with limited fresh information.